CLLS (Cellectis) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLLS Cellectis SA CLLS
60 GF Score
Price $2.69
GF Value $3.25
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cellectis Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

CLLS
60GF Score
Cellectis SA CLLS
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (CLLS) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of $2.69 is trading 17.2% below its estimated GF Value™ of $3.25. GuruFocus considers Cellectis to be Modestly Undervalued.

Key valuation signals for CLLS:

  • Dividend-Payout-to-FFO:
  • GF Value™: $3.25 vs. price of $2.69 (17.2% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CLLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
60GF Score

Get the complete analysis for CLLS

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.69
Price
$3.25
GF Value